Allergic Reaction Clinical Trial
Official title:
Within-tester Repeatability and Between-tester Reproducibility of Skin Test Endpoint Titration
NCT number | NCT03489694 |
Other study ID # | STE-2018 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 4, 2018 |
Est. completion date | July 25, 2018 |
Verified date | October 2018 |
Source | University of Saskatchewan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will examine the within-tester repeatability and between-tester reproducibility of skin test endpoint titrations performed in those with allergic sensitivities.
Status | Completed |
Enrollment | 17 |
Est. completion date | July 25, 2018 |
Est. primary completion date | July 25, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - must have allergic sensitivities confirmed by a skin prick test (or historically) to at least one of the study allergens Exclusion Criteria: - skin condition on the forearms - if there is a situation where interpretation of skin reactions would be difficult (e.g. sleeve tattoos, scarring) - regular use of anti-histamines (assessed on a case-by-case basis) |
Country | Name | City | State |
---|---|---|---|
Canada | Asthma Research Lab - University of Saskatchewan | Saskatoon | Saskatchewan |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Within-tester repeatability | Comparison of wheal size (in mm) of skin reactions caused by a tester (duplicate skin pricking for each concentration of allergen administered) | 10 minutes post skin pricking | |
Primary | Between-tester reproducibility | Comparison of wheal size (in mm) of skin reactions caused by three different testers | approximately 3 weeks (one week washout between tests) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04058743 -
Nickel Sensitivity
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Active, not recruiting |
NCT05605795 -
Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
|
||
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Completed |
NCT04510376 -
Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
|
N/A | |
Completed |
NCT05185479 -
Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
|
||
Recruiting |
NCT05185362 -
Epidemiology of Pecan Nut Allergy
|
||
Completed |
NCT03525496 -
Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
|
||
Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
Enrolling by invitation |
NCT05670756 -
Preoperative Survey to Evaluate Patient Allergy
|
||
Recruiting |
NCT05462444 -
Development of Personalized Balanced Nutrition Concept Through an IT Platform
|
||
Not yet recruiting |
NCT05284253 -
Is There an Allergy to Pure Metallic Gold Microparticles?
|
N/A | |
Completed |
NCT03157505 -
Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01436617 -
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
|
Phase 2 | |
Not yet recruiting |
NCT05533385 -
Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.
|
N/A | |
Not yet recruiting |
NCT05532566 -
Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
|
N/A | |
Recruiting |
NCT06011603 -
Prineo Sensitivity Dressing Study
|
Phase 4 | |
Completed |
NCT04761822 -
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
|
Phase 2 | |
Recruiting |
NCT05367531 -
Assessment of Injectable Medication Platforms
|
N/A |